Department of Otolaryngology-Head and Neck Surgery, Christchurch Hospital, Christchurch, New Zealand.
Otol Neurotol. 2011 Aug;32(6):933-6. doi: 10.1097/MAO.0b013e3182255933.
To measure dexamethasone concentrations in the plasma and perilymph of the human ear after intravenous (IV) and intratympanic (IT) administration and to compare these with previous studies with methylprednisolone.
Patients were administered dexamethasone by the IT or IV routes approximately 0.5 to 2 hours before cochlear implantation. The IT dose of 1.6 to 7.2 mg (0.4-1.8 ml of a 4 mg/ml solution) of dexamethasone sodium phosphate was administered by injection into the middle ear cavity through the external auditory canal via a 27-gauge needle passed through a small anterosuperior myringotomy. The IV dose of dexamethasone sodium phosphate was 0.17 mg/kg given as a single injection for 30 seconds. A sample of perilymph (approximately 20 μl) was collected using a needle passed through the round window, and blood was sampled simultaneously. Concentrations of free dexamethasone and dexamethasone sodium phosphate were measured using a validated liquid chromatography-tandem mass spectrometry method.
In the 22 patients studied, 22 perilymph samples and 19 plasma samples were available and suitable for measurement. The median perilymph concentration of dexamethasone after IV injection of 0.17 mg/kg was 0.016 mg/L (n = 9; range, 0.008-0.17), and 1.4 mg/L (n = 13; range, 0.1-16.3) after IT administration of approximately 4 mg. Perilymph concentrations were approximately 88-fold higher after IT compared with IV administration (p = 0.0004) or approximately 260 fold after correction for dosage. The median plasma concentration of dexamethasone after IV injection was 0.12 mg/L (n = 7; range, 0.07-0.14) and 0.003 mg/L (n = 12; range, <0.0005-0.005) after IT injection. Plasma concentrations were approximately 40-fold lower (p = 0.0005) or approximately 13-fold lower after dose correction. Concentrations of dexamethasone sodium phosphate were more variable and were even higher in perilymph and lower in plasma.
Administration of dexamethasone IT results in much higher perilymph concentrations and much lower plasma concentrations compared with IV administration.
测量静脉(IV)和鼓室内(IT)给药后人类耳血浆和外淋巴中地塞米松的浓度,并与先前使用甲泼尼龙的研究进行比较。
患者在大约 0.5 至 2 小时前接受 IT 或 IV 途径的地塞米松治疗,然后进行耳蜗植入。通过穿过小的前上鼓膜切开术的 27 号针头将磷酸地塞米松钠的 IT 剂量 1.6 至 7.2 毫克(0.4-1.8 毫升 4 毫克/毫升溶液)注射到中耳腔中。静脉注射地塞米松磷酸钠 0.17 毫克/千克,持续 30 秒。使用穿过圆窗的针采集约 20 μl 的外淋巴液样本,并同时采集血液样本。使用经过验证的液相色谱-串联质谱法测量游离地塞米松和地塞米松磷酸钠的浓度。
在研究的 22 名患者中,获得并适合测量 22 个外淋巴液样本和 19 个血浆样本。静脉注射 0.17 毫克/千克地塞米松磷酸钠后的中位血浆浓度为 0.016 毫克/升(n = 9;范围,0.008-0.17),而 IT 给药后约 4 毫克的浓度为 1.4 毫克/升(n = 13;范围,0.1-16.3)。与 IV 给药相比,IT 后外淋巴液中的浓度高约 88 倍(p = 0.0004)或经剂量校正后高约 260 倍。静脉注射地塞米松磷酸钠后的中位血浆浓度为 0.12 毫克/升(n = 7;范围,0.07-0.14),IT 注射后为 0.003 毫克/升(n = 12;范围,<0.0005-0.005)。血浆浓度低约 40 倍(p = 0.0005)或经剂量校正后低约 13 倍。地塞米松磷酸钠的浓度变化更大,在外淋巴液中的浓度更高,在血浆中的浓度更低。
与 IV 给药相比,IT 给予地塞米松可导致更高的外淋巴液浓度和更低的血浆浓度。